Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,409 across all filing types
Latest filing 2026-03-24 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Regulatory Filings Classification · 20% confidence The document is a corporate press release announcing regulatory approval of a pharmaceutical product in Japan. It does not present financial results, governance materials, or regulatory filings like annual or quarterly reports, nor does it announce a specific meeting or share transaction. Therefore, it is best categorized as a general regulatory announcement or miscellaneous corporate filing under the fallback category RNS.
2026-03-24 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 95% confidence The document is titled 'Disclosure of trading in own shares' and contains detailed tables listing transactions of the company's own shares over various dates. The content focuses on the company's purchases of its own shares, including quantities and transaction details. There is no indication of financial results, management discussion, voting results, or other report types. The document is not a report publication announcement or a certification. The primary subject is the company's transactions in its own shares, which aligns with the category for reporting share repurchases or issuances by the company itself.
2026-03-23 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2026-03-23 French
Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing that the FDA has granted 'breakthrough therapy designation' to their experimental drug venglustat for Gaucher disease type 3. It details clinical trial results (LEAP2MONO), provides background on the disease, and includes standard corporate boilerplate, contact information, and forward-looking statements. As it is a general regulatory announcement regarding drug development status and does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a Regulatory Filing (RNS).
2026-03-18 French
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi announcing that the FDA has granted 'Breakthrough Therapy designation' to their investigational drug venglustat. It details the clinical study results (LEAP2MONO) and regulatory status of the drug. As this is a general corporate announcement regarding regulatory milestones and product development that does not fit into specific financial reporting categories like 10-K or IR, it is classified as a Regulatory Filing (RNS).
2026-03-18 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' (Declaration of transactions on own shares) and provides a detailed table of share repurchase transactions conducted by Sanofi over a specific period (March 2020). This aligns perfectly with the definition of 'Transaction in Own Shares' (POS), which covers reports of companies buying back their own shares.
2026-03-16 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.